Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05863351 · ClinicalTrials.gov registry record · Phase 3
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
A Phase 3 study of Metastatic Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v8, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- Phase 3
- Development phase
- 472
- Enrollment target
- 20
- Study locations
NCT05863351 is a Phase 3 study of Metastatic Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v8 that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 472 participants, above the 131-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (260% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05863351, a Phase 3 study of Metastatic Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v8, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 472 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get for metastatic kidney cancer which includes systemic therapy such as immunotherapy (given through the veins) and/or small molecular inhibitor (tablets taken by mouth). Radiotherapy uses high energy x-rays to kill cancer cells and shrink tumors. SAbR uses special equipment to position a patient and deliver radiation to tumors with high precision. Giving SAbR prior to systemic therapy may kill more tumor cells than the usual approach, which is systemic therapy alone.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- OTHER Questionnaire Administration
- PROCEDURE Stereotactic Ablative Radiotherapy
- PROCEDURE Systemic Therapy
Study Locations (20)
Illinois
- OSF Saint Joseph Medical Center - Bloomington
- Illinois CancerCare-Bloomington - Bloomington
- Illinois CancerCare-Canton - Canton
- Illinois CancerCare-Carthage - Carthage
- Centralia Oncology Clinic - Centralia
- Northwestern University - Chicago
- University of Illinois - Chicago
- Carle at The Riverfront - Danville
- Cancer Care Specialists of Illinois - Decatur - Decatur
- Decatur Memorial Hospital - Decatur
Colorado
- UCHealth University of Colorado Hospital - Aurora
- Poudre Valley Hospital - Fort Collins
- Cancer Care and Hematology-Fort Collins - Fort Collins
- UCHealth Greeley Hospital - Greeley
- UCHealth Highlands Ranch Hospital - Highlands Ranch
- Medical Center of the Rockies - Loveland
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 472 participants |
| Start Date | 2023-09-07 |
| Est. Completion | 2037-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05863351
The ClinicalTrials.gov registry entry for NCT05863351 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 472 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 131-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (260% higher). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT05863351 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT05863351 about?
NCT05863351 is a clinical study titled "Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study". This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in t...
What is the current status of trial NCT05863351?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 472 participants. The study started on 2023-09-07. Estimated completion is 2037-08-01.
What conditions does trial NCT05863351 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8.
What interventions are being tested in trial NCT05863351?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Questionnaire Administration (OTHER), Stereotactic Ablative Radiotherapy (PROCEDURE), Systemic Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT05863351?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05863351 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
RECRUITING · Phase 3
-
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
RECRUITING · Phase 3
-
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
ACTIVE NOT RECRUITING · Phase 3
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RECRUITING · Phase 2
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
Explore more on PlainTrial
Metastatic Renal Cell Carcinoma
All registered trials for this condition
Stage IV Renal Cell Cancer AJCC v8
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.